Enliven Therapeutics
Develops small-molecule therapies centered on ELVN-001 for chronic myeloid leukemia.
$57.69
After-hours close−0.16 (−0.27%)
At close$57.85(−4.38%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.43 | — | — |
| Aug 2026 | −$0.39 | −$0.49 | −26.6% |
| May 2026 | −$0.44 | −$0.38 | +13.6% |
| Mar 2026 | −$0.42 | −$0.48 | −14.3% |
| Nov 2025 | −$0.43 | −$0.32 | +25.6% |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.43 | — | — | — | — | — |
| Aug 5, 2026 | −$0.39 | −$0.49 | −26.6% | — | — | — |
| May 7, 2026 | −$0.44 | −$0.38 | +13.6% | — | — | — |
| Mar 3, 2026 | −$0.42 | −$0.48 | −14.3% | $12.5K | — | — |
| Nov 12, 2025 | −$0.43 | −$0.32 | +25.6% | $8.3K | — | — |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | ||||||
| Aug 13, 2025 | ||||||
| May 14, 2025 | ||||||
| Mar 13, 2025 | ||||||
| Nov 13, 2024 | ||||||
| Aug 13, 2024 | ||||||
| May 14, 2024 | ||||||
| Mar 14, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 11, 2023 | ||||||
| Feb 10, 2023 | ||||||
| Oct 25, 2022 | ||||||
| Aug 3, 2022 | ||||||
| May 6, 2022 | ||||||
| Mar 15, 2022 | ||||||
| Nov 9, 2021 | ||||||
| Aug 6, 2021 | ||||||
| May 11, 2021 | ||||||
| Mar 5, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 14, 2020 | ||||||
| May 7, 2020 | ||||||
| Mar 11, 2020 | ||||||
| Dec 31, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Mar 31, 2019 | ||||||